Cartilage is a primary target tissue for the IGFs. The mitogenic activity of these peptides is regulated by a family of high-affinity IGF-binding proteins (IGFBP-1 to -6). We characterized the IGFBPs produced by cultured chondrocytes derived from rib cartilage of prepubertal rabbits. Culture medium, which had been conditioned by these cells for 48 h showed bands of 22 kDa, 24 kDa and a 31/32 kDa doublet by Western ligand blotting with [ 125
I]IGF-II. When the cells were grown in the presence of increasing amounts of IGF-I or IGF-II, the 31/32 kDa doublet increased in intensity (reaching a plateau of about 11-fold stimulation between 2 and 10 nM IGF-I). The 22 kDa and 24 kDa bands increased only slightly while a 26 kDa band became faintly visible. By Western immunoblotting the 31/32 kDa doublet was identified as
Introduction
The insulin-like growth factors (IGF-I and IGF-II) are important growth factors in postnatal longitudinal growth in mammals (D'Ercole 1996 , Van Buul-Offers 1996 . Gene expression for IGF-II and both IGF-I and IGF-II receptors has been detected in epiphyseal growth plates of rats and mice (Shinar et al. 1993 , Wang et al. 1995 . Although it is not certain whether IGF-I is produced locally by growth plate cartilage (Nilsson et al. 1986 , Shinar et al. 1993 , Lazowski et al. 1994 , Wang et al. 1995 , this peptide clearly has important effects on proteoglycan synthesis and proliferation of this tissue (Van Buul-Offers et al. 1994 , Salmon & Burkhalter 1997 . The actions of both IGFs are modulated by non-covalent association with IGF-binding proteins (IGFBP-1 to -6) (Rajaram et al. 1997 , Clemmons 1998 . The affinity of the IGFBPs for their ligands is, in turn, regulated by proteolytic enzymes, which cleave binding proteins at specific sites (Fowlkes 1997) .
The regulation of expression of IGFBPs and their proteases has been extensively characterized in many types of cultured cells, including osteoblasts (Hassager et al. 1992 , Conover & Kiefer 1993 , Mohan 1993 , McCarthy et al. 1994 and articular chondrocytes (Froger-Gaillard et al. 1989 , Olney et al. 1993 , DiBattista et al. 1996 , Matsumoto et al. 1996a ,b, Sunic et al. 1998 . Much less information is available on IGFBP production by growth plate cartilage. In situ hybridization indicated the presence of only IGFBP-6 mRNA in postnatal mouse and rat growth plates (Wang et al. 1995) . Chondrocytes cultured from fetal bovine growth plates secreted IGFBP-3 and unidentified binding proteins of 24 and 29 kDa (Olney et al. 1993) . Production of IGFBP-3 and the 29 kDa protein was increased by IGF-I. In contrast, costal growth plate chondrocytes from sheep were found to produce primarily IGFBP-2 (Borromeo et al. 1996) .
Glucocorticoids have effects on skeletal tissues, which are often opposite to the effects of the IGFs. When used in the clinic, their most important side-effects are growth suppression (Allen 1996) and osteoporosis (Lane & Lukert 1998) . In rat epiphyseal chondrocytes, dexamethasone suppresses production of IGF-I and expression of both growth hormone (GH) and IGF-I receptors ( Jux et al. 1998) . Similarly, bone cells are important target cells for glucocorticoids, resulting in decreased production of IGF-I (Delany & Canalis 1995) and IGFBPs (Okazaki et al. 1994) . The effects of glucocorticoids on IGFBPs in cartilage are unknown.
We initiated a study to more extensively characterize the secretion and regulation of production of IGFBPs by chondrocytes. Using chondrocytes from costal cartilage of growing rabbits, we particularly focussed on the effects of IGF-I and dexamethasone.
Materials and Methods

Materials
Recombinant human IGF-I and IGF-II were kindly provided by Eli Lilly & Co., Indianapolis, IN, USA. Long-R3 IGF-I was from GroPep Pty Ltd (Adelaide, Australia). Recombinant human IGFBP-5 (produced in insect cells) was purchased from A F Schützdeller Biochemicals, Tübingen, Germany. Dexamethasone was from the pharmacy of our own hospital. LY294002 was from Biomol (Plymouth Meeting, PA, USA).
Isolation and culture of chondrocytes
Ribs of 5-to 7-week-old New Zealand White rabbits were dissected under sterile conditions and the cartilage was carefully cleaned, stripped of perichondrium and cut into small pieces. The tissue was digested with 1 mg/ml protease (P-6911; Sigma Chemical Co., St Louis, MO, USA) in Dulbecco's modified Eagle's medium containing 1 g/l glucose, 4 mM -glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies Ltd, Paisley, UK) for 30 min at 37 C, followed by digestion with 0·5 mg/ml collagenase (Sigma; C-9891) in the same medium supplemented with 10% fetal calf serum (Life Technologies Ltd) for 6 h at 37 C. The cells released from the tissue were centrifuged, counted in a Bürker counting cell and seeded in 75 cm 2 tissue culture flasks (40 000-80 000 cells/cm 2 ). The cells were grown at 37 C in a 5% CO 2 and humid atmosphere. When confluence was reached (usually after 4 days) the cells were detached using 0·05% trypsin/0·02% EDTA. Generally, second passage cells were used for experiments, but identical results were obtained with first and third passage cells. When cells were to be treated with growth factors and hormones followed by Western blotting or protease assay, they were seeded (40 000 or 80 000 cells per well) on 24-well plates. For isolation of RNA from cells, 1-3 10 6 cells were seeded in 75 cm 2 flasks. The monolayer cultures of cells isolated from rib cartilage remained differentiated chondrocytes as determined by their characteristic polygonal shape and expression of type II collagen and aggrecan (as determined by in situ hybridization and Northern blotting, Fig. 6 Conditioned medium was prepared by first preincubating the cells in serum-free medium for 2 h, after which the medium was changed and hormones or peptides were added as indicated in the text. Unless indicated otherwise, media were collected after 48 h, centrifuged for 10 min at 3000 g (4 C) and stored at -80 C.
Western blotting
Chondrocyte-conditioned medium (1 ml) was concentrated tenfold on Centricon-10 ultrafiltration membranes (Millipore Corp., Bedford, MA, USA) and loaded on a 12% gel for non-reducing SDS-PAGE. IGFBPs were visualized by electrotransfer to PVDF membranes (Immobilon-P; Millipore) followed by incubation with [ 125 I]IGF-II (ligand blotting) (Van Buul-Offers et al. 1994) . Molecular weights were calculated using broad range markers (Bio-Rad Laboratories, Hercules, CA, USA) as standards. Quantitation of the bands on the blots was performed by phosphorimaging using a Bio-Rad GS-363 molecular imager system together with molecular analyst software.
For immunoblotting, 10 ml conditioned medium from 75 cm 2 flasks was concentrated 50-fold by consecutive lyophylization and ultrafiltration. IGFBP-5 was detected using a goat antibody directed against a peptide sequence from human IGFBP-5 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 1/5000 dilution, followed by a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.) at 1/8000 dilution. The bands were visualized using the SuperSignal chemiluminescent substrate of Pierce (Rockford, IL, USA) and Hyperfilm ECL film (Amersham International plc, Little Chalfont, Bucks, UK).
IGFBP-5 protease assay
The presence of proteases in chondrocyte-conditioned medium which can degrade IGFBP-5 was determined essentially as described for IGFBP-3 (Koedam et al. 1998) .
As a substrate, recombinant human IGFBP-5 (produced in yeast) which was kindly provided by Dr J Zapf, Zürich, Switzerland (Kiefer et al. 1992 ) was used. The protein was iodinated with Na 125 I (Amersham International plc) by the chloramine-T method. Unbound radioactivity was removed on a PD-10 (Sephadex G-25) column (Pharmacia Biotech AB, Uppsala, Sweden). Concentrated medium (10 µl) was mixed with 40 000 c.p.m. [ 125 I]IGFBP-5 in a total volume of 30 µl 100 mM TrisHCl, pH 7·4, containing 0·5 mM CaCl 2 and 1% Triton X-100. The mixture was incubated for 5 h at 37 C and the reaction was stopped by the addition of 50 µl SDS-sample buffer (containing 10% 2-mercaptoethanol) and boiling for 3 min. The samples were electrophoresed on a 12% polyacrylamide gel, followed by staining in Coomassie Brilliant Blue and autoradiography using Fuji RX medical X-ray film. Quantitation of the bands was performed by phosphorimaging of the gel. The amount of proteolysis was expressed as the intensity in each lane that was associated with the degradation products of IGFBP-5 relative to the total intensity in the lane. The molecular weight of the fragments was calculated using broad-range molecular weight markers (Bio-Rad) as standards.
RNA isolation and Northern blotting
Cells in confluent 75 cm 2 flasks (kept for 48 h under serum-free conditions in the presence of hormones as indicated) were washed with phosphate-buffered saline, scraped from the plastic and centrifuged. RNA was isolated with TriPure isolation reagent (BoehringerMannheim GmbH, Mannheim, Germany) according to the manufacturer's instructions. Tissue from rabbit liver and kidney was first homogenized with a IKA-UltraTurrax T25 (Janke & Kunkel GmbH, Stufen, Germany) homogenizer in ice-cold TriPure reagent. RNA (20 µg) was separated on a denaturing 1% agarose gel and blotted onto a Nylon membrane (Hybond-N+; Amersham International plc) using a vacuum blotter (Appligene-Oncor, Illkirch, France). The filter was prehybridized with 50 µg/ ml denatured salmon sperm DNA (Sigma) in hybridization mix (0·1 g/ml dextran sulfate, 5 Denhardt's, 3 SSC, 0·1% SDS) and hybridized with the indicated DNA probes for 16 h at 55 C in hybridization mix. Probes were random prime labeled with [ -32 P]dCTP using the Rediprime system (Amersham Pharmacia Biotech). The blots were washed up to a stringency of 1 SSC, 0·1% SDS at 55 C.
The following cDNA probes were used: mouse aggrecan (474 bp) and collagen types I (321 bp), II (405 bp) and IX (444 bp) obtained from Dr E Vuorio, Turku, Finland (Metsaranta et al. 1991 , Glumoff et al. 1994 . Mouse IGFBP-2 (480 bp), -3 (201 bp) and -5 (282 bp) were from Dr S L S Drop, Rotterdam, The Netherlands (Schuller et al. 1994) . The household gene GAPDH was probed with a rat cDNA sequence (1·2 kb) which was a gift from Dr J S Sussenbach, Utrecht, The Netherlands (Fort et al. 1985 , Dufourny et al. 1997 . Quantitation of the abundance of transcripts was performed by phosphorimaging of the blot, and values were corrected for GAPDH levels.
Results
Characterization of secreted IGFBPs and regulation by IGFs
In many cell types the production of IGFBPs is regulated by IGF-I. Therefore, we first determined the effect of IGF-I on the accumulation of IGFBPs by the chondrocytes. In the presence of 10 nM IGF-I, major bands of 31/32 kDa appeared on Western ligand blots in a timedependent fashion (Fig. 1A) . A minor and diffuse third band was often seen migrating just above the major doublet. After 48 h, the intensity of the doublet increased between 6-and 18-fold (average 10·9 4·7-fold .., six independent experiments) over the control cells cultured in the absence of IGF-I. In some experiments, the cells were trypsinized and counted in a Bürker counting cell. Since the number of cells increased twofold at most in response to IGF-I, this can only partly account for the increase in production of this IGFBP. Figure 1B shows the dose-dependent increase of the 31/32 kDa doublet. The maximum production was reached at 10 nM, while in some experiments a decrease was found at 50 nM IGF-I (not shown). We used immunoblotting with an antibody directed to human IGFBP-5 to identify the 31/32 kDa doublet (Fig. 2 ). An immunoreactive doublet comigrating with the doublet on the ligand blot was induced by IGF-I. In addition, the species produced by the cells co-migrated with recombinant IGFBP-5 (Fig. 2) . Therefore, the major IGF-I-inducible IGFBP produced by costal chondrocytes was identified as IGFBP-5.
In the absence of IGF-I, a band of variable intensity was visible at 24 kDa (Figs 1, 3 and 4) . This band, which probably represents IGFBP-4, was not regulated by IGF-I. Unidentified bands at 22 and 26 kDa were faintly visible only in the presence of 10 nM IGF-I (Figs 1 and 3) . Since no antibodies are available that specifically recognize IGFBPs in rabbits (other than the anti-IGFBP-5 antibody that we used), the various bands have not been positively identified (Nason et al. 1996) and thus are designated by comparing with the migration pattern in humans.
The potency of IGF-II to induce IGFBP-5 production was similar to that of IGF-I. In duplicate experiments (results not shown), 10 nM IGF-II gave a 7·9-fold increase, while IGF-I gave a 7·8-fold increase in IGFBP-5 levels in the culture medium. Long-R3 IGF-I, which is an analog with low affinity for IGFBPs but almost normal affinity for the type 1 IGF receptor (Francis et al. 1992 ) was slightly less potent: a 6·3-fold increase was found at 10 nM. Insulin (10 nM), which does not bind to IGFBPs and has a low affinity for the type 1 IGF receptor, showed only a 2·2-fold increase.
Effects of dexamethasone
The effects of the glucocorticoid dexamethasone were tested in the absence and presence of 10 nM IGF-I (Fig.  3) . In keeping with the result shown in Fig. 1 , IGF-I resulted in a 10·7-fold increase of the 31/32 kDa doublet, which was identified as IGFBP-5 (Fig. 2) . Dexamethasone resulted in a dose-dependent suppression of IGFBP-5 release by chondrocytes (Fig. 3) . This was most discernible in the presence of 10 nM IGF-I, where half-maximal inhibition was reached between 2 and 20 nM dexamethasone (Fig. 3B) . The very weak band at 22 kDa was also strongly inhibited, while the 24 kDa band was relatively less affected. Dexamethasone did not affect the 26 kDa band. In contrast, dexamethasone consistently increased the production of a doublet at 39/41 kDa, which resembles the migration pattern typical of IGFBP-3. In a separate experiment (results not shown), the 39/41 kDa doublet produced by the cells was shown to co-migrate with the predominant IGFBP species in rabbit serum and in human serum. In human serum, this species was identified as IGFBP-3 by immunoblotting.
Effect of LY294002 on IGFBP-5 production
Stimulation of IGFBP-5 production by members of the IGF family appears to parallel their affinity for the type 1 IGF receptor (IGF-IdIGF-II>Long-R3 IGF-I> > insulin). Therefore, a receptor-mediated mechanism is likely. To investigate which intracellular signaling route is involved, we used LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) (Vlahos et al. 1994) . Figure 4 shows that this drug dose-dependently prevented the stimulation of IGFBP-5 production by IGF-I (at 10 nM IGF-I, IGFBP-5 was inhibited by 49% and 91% at 5 µM and 25 µM LY294002 respectively). The LY294002 concentrations used did not result in any changes in cell morphology or detachment of cells. In addition, the 24 kDa band, which is visible below the IGFBP-5 bands, was not influenced by 5 µM LY294002. Therefore, the inhibitory effect on IGF-I-induced IGFBP-5 production does not appear to be the result of a general toxicity. Although we did not independently investigate the signaling route which utilizes the mitogenactivated protein kinase, the IGF-I-dependent induction of IGFBP-5 appears to rely on the activity of PI 3-kinase.
Effect of IGF-I on proteolysis of IGFBP-5
Many cell types, including chondrocytes, produce specific proteases, which can cleave IGFBPs (Matsumoto et al. 1996a , Fowlkes 1997 . We tested the conditioned medium from the costal chondrocytes for the presence of IGFBP-5 proteases using [ shown in Fig. 5 , the cells secreted such proteases, which resulted in the cleavage of the 36 kDa IGFBP-5 into fragments of 23 and 17 kDa. Because the samples were electrophoresed under reducing conditions, IGFBP-5 migrates at a higher apparent molecular weight than observed on the Western blots (Figs 1-4) . Addition of EDTA inhibited degradation, which is consistent with the observation that IGFBP proteases are usually divalent cation-dependent.
We tested the effect of IGF-I on proteolysis of IGFBP-5 by either including IGF-I during the 5-h incubation of [ 125 I]IGFBP-5 with conditioned medium or by culturing the cells in the presence of IGF-I. The addition of IGF-I together with the conditioned medium had no effect on IGFBP-5 proteolysis. When the medium was conditioned in the presence of IGF-I, however, proteolysis was reduced by approximately 50%, to the degree of spontaneous degradation seen in the absence of conditioned medium (Fig. 5) . This result indicates that IGF-I may not directly protect IGFBP-5 against attack by proteolytic enzymes, but may instead induce release of protease inhibitors by the cells or, conversely, inhibit the release of proteases.
Regulation of mRNA
Northern blotting experiments of total RNA from cultured chondrocytes were performed to study the effects of IGF-I and dexamethasone on steady-state mRNA levels ( Fig. 6 and Table 1 ). Hybridization with an IGFBP-5 probe revealed a single 6·0 kb transcript (Fig. 6) . The same transcript was detected in high abundance in rabbit kidney and weakly in the liver. Treatment with 10 nM IGF-I resulted in a 2·2-fold increase in mRNA abundance, while 20 nM dexamethasone caused a 69% decrease. Treatment with the combination of IGF-I and dexamethasone resulted in a 34% decrease compared with non-treated cells.
IGFBP-3 mRNA was readily detected in liver (2·2 kb) and weakly in kidney, but not in chondrocytes. Treatment with dexamethasone resulted in a detectable level of the IGFBP-3 transcript (Fig. 6 ). This result parallels the induction of IGFBP-3 protein by dexamethasone (Fig. 3) .
In addition to IGFBP-5 and -3, we looked for IGFBP-2 mRNA, because IGFBP-2 was reported to be an important IGFBP in costal chondrocytes from 4-week-old lambs (Borromeo et al. 1996) . Although a 1·6 kb mRNA was detected in rabbit liver, this messenger was not detected in the kidney or in the cultured chondrocytes (not shown).
Expression of the chondrocyte-specific gene for collagen II (4·9 kb) was not affected by either IGF-I or dexamethasone ( Fig. 6 and Table 1), while both IGF-I and dexamethasone resulted in minor decreases (15 and 30% respectively) of the aggrecan mRNA (8·0 kb).
Discussion
In this study we have characterized the production and regulation of IGFBPs by cultured rabbit costal chondrocytes. The cells were derived from the cartilage away from the growth plates at the osteochondral junctions and thus have been regarded as resting chondrocytes (Boyan et al. 1988) . They do proliferate (Schwartz et al. 1998) , however, and respond to IGF-I, a growth factor which is important for longitudinal growth, by incorporation of [
S]sulfate and [
3 H]thymidine. They are part of the endochondral lineage and express genes typical for cartilage matrix proteins. Therefore, these cells may serve as an initial model for growth plate chondrocytes. Presently, we are comparing costal chondrocytes with chondrocytes derived from tibial growth plates.
Under serum-free conditions, small amounts of IGFBPs are detectable at 24 kDa and 31/32 kDa by the Western ligand blot method. The 31/32 kDa doublet, which was identified as IGFBP-5 by Western immunoblot, is strongly induced by IGF-I and IGF-II. The frequent appearance of a third, diffuse, band migrating above the doublet makes the pattern very similar to that observed for IGFBP-5 secreted by osteoblastic cells (Conover & Kiefer 1993) . Unlike the study by Conover & Kiefer (1993) , however, we did not observe any change in the migration pattern upon treatment of the conditioned medium with neuraminidase and O-glycosidase (our unpublished results). The reason for this discrepancy is unclear, but if IGFBP-5 is O-glycosylated, side chains other than sialic acid may preclude hydrolysis of the sugar by O-glycosidase.
Various patterns of IGFBP production by cultured chondrocytes have been reported. Our results most closely resemble those of Matsumoto et al. (1996b) in rat articular chondrocytes. They also found IGFBP-5 to be the major IGF-I-inducible species. The first published investigation of IGFBP production by chondrocytes (Froger-Gaillard et al. 1989 ) also reported a dominant, IGF-inducible, 30/31 kDa doublet in rabbit (articular) chondrocytes, although its identity was not established. In contrast, IGFBP-2 was the most abundant species in sheep chondrocytes (Borromeo et al. 1996 , Sunic et al. 1998 . IGFBP-3 production was prominent in human articular chondrocytes (Olney et al. 1995 , DiBattista et al. 1996 and weaker in IGF-I-stimulated bovine chondrocytes of various origin (Olney et al. 1993) . Further study will be needed to establish whether the observed differences are caused by species differences, the type of cartilage from which the chondrocytes were derived, or variation in experimental procedures.
IGFBPs have not yet been detected at the protein level in rib or growth plate cartilage in situ. The report by Wang et al. (1995) suggests that only mRNAs for IGFBP-5 and -6 are expressed, primarily in the early stages of chondrogenesis. This does not preclude, however, the local induction of specific IGFBPs by growth factors or migration of the proteins from other tissues.
IGF-I both increased steady-state levels of IGFBP-5 mRNA and protected the protein against proteolysis, indicating that in costal chondrocytes the IGFBP-5 level is regulated by a combination of these mechanisms. In cultures of skeletal cells, IGF-I has been shown to increase IGFBP-5 levels, but the underlying mechanism has been found to vary. Interaction with IGFs and inhibition of proteolytic degradation were primarily involved in ovine articular chondrocytes (Sunic et al. 1998) and in human (Conover & Kiefer 1993 ) and rat osteosarcoma cells. In contrast, in rat primary osteoblastic cells (Dong & Canalis 1995) , IGF-I increased the transcription rate of the IGFBP-5 gene. In rat articular chondrocytes (Matsumoto et al. 1996b) , as in our study, both mechanisms were involved.
Our experiments using IGF-II, Long-R3 IGF-I and insulin indicate that the potency of these peptides to increase IGFBP-5 parallels their affinity to the type 1 IGF receptor, and not to binding proteins. Therefore, the receptor is likely to mediate this effect. We have used a specific inhibitor of PI 3-kinase, LY294002 (Vlahos et al. 1994) , as a first approach to identify the intracellular signaling pathway responsible for inducing IGFBP-5. Since this inhibitor strongly inhibited the response to IGF-I, the PI 3-kinase pathway appears to be important. Rousse et al. (1998) studied the regulation of IGFBP-5 in mouse myoblasts and also found that it was upregulated as a result of activation of the type 1 IGF receptor. In contrast to our results, however, this upregulation was not affected by the PI 3-kinase inhibitors LY294002 and wortmannin. Similar discrepancies have been found in the intracellular signaling pathways linking activation of the type 1 IGF receptor to the mitogenic response. For instance, IGF-Iinduced proliferation of myoblasts was dependent on the mitogen-activated protein kinase pathway (Coolican et al. 1997) , while in MCF-7 human breast cancer cells the proliferative actions of IGF-I were dependent on PI 3-kinase activity (Dufourny et al. 1997) . Further study will be needed to resolve if these differences are due to experimental conditions or the use of different cell types.
With the exception of one report (DiBattista et al. 1996) , regulation of chondrocyte IGFBP expression by glucocorticoids has not been studied before. Our study shows that dexamethasone strongly inhibits IGFBP-5 expression by chondrocytes. Since mRNA levels are decreased in parallel, dexamethasone probably regulates IGFBP-5 at the transcriptional level. In contrast, IGFBP-3 was upregulated by dexamethasone, both at the mRNA and protein level.
Glucocorticoids have important effects on skeletal tissue, resulting in osteoporosis and growth retardation in experimental animals and in clinical use. IGF-I and glucocorticoids often have opposite effects on the skeleton and changes in components of the GH/IGF axis are therefore believed to be important mediators of the actions of glucocorticoids (Tönshoff & Mehls 1996 , Canalis 1998 , Jux et al. 1998 . For instance, IGF-I is mitogenic and promotes matrix production, while glucocorticoids inhibit proliferation and increase matrix degradation. In addition, dexamethasone decreases expression of IGF-I as well as its receptor in rat epiphyseal chondrocytes (Jux et al. 1998) . The opposing effects on IGFBP-5 expression by chondrocytes add to this general picture. The differential regulation of IGFBPs expressed by cartilage may be relevant to the growth-inhibiting effect of glucocorticoids if one considers the potentiating effect of IGFBP-5 on IGF-I action (Andress & Birnbaum 1992 ) and the inhibitory role of IGFBP-3 (Rajaram et al. 1997) . IGFBP-3 may also display IGF-I-potentiating activity, however (De Mellow & Baxter 1988 , Conover 1991 , which makes the significance of these changes unpredictable. In order to unravel the roles of IGFBP-3 and -5 in chondrocyte proliferation, their matrix association, proteolysis, concentrations relative to the IGFs etc. must be taken into account.
Figure 6
Northern blot analysis. Chondrocytes were treated with 10 nM IGF-I or 20 nM dexamethasone (DEX) or the combination of both for 48 h under serum-free conditions, after which total RNA was isolated and hybridized with 32 P-labeled probes as indicated. Contr; control cells cultured without growth factor or hormone. mRNAs of selected IGFBP, and chondrocyte-specific matrix proteins were detected. The household gene GAPDH was used to correct for RNA loading.
Many studies have addressed the regulation of IGFBPs by glucocorticoids in vivo and in vitro, but the results vary between IGFBPs, the types of cells studied and the experimental conditions. In accordance with our results, dexamethasone and cortisol consistently decrease IGFBP-5 levels in bone cells (Okazaki et al. 1994) and fibroblasts (Conover et al. 1995) . In contrast to our results, however, IGFBP-3 was found to be downregulated by dexamethasone in bone cells (Okazaki et al. 1994) , hepatic cells (Villafuerte et al. 1995) and articular chondrocytes (DiBattista et al. 1996) . Regulation of IGFBP-3 by glucocorticoids was also studied in vivo. Both in rats and in humans, administration of dexamethasone led to an increase in serum IGFBP-3 levels (Luo & Murphy 1990 , Miell et al. 1993 . Obviously, the effects of glucocorticoids are broad and complex, and regulation of IGFBP-3 in vivo may be through an indirect mechanism.
In conclusion, costal chondrocytes produce predominantly IGFBP-5, which is upregulated by IGFs and downregulated by dexamethasone. Concomitant induction of IGFBP-3 by dexamethasone may contribute to the growth-arresting effect of this potent glucocorticoid.
